The Blood and Marrow Transplant Program at Northside Hospital is a collaboration between The Blood and Marrow Transplant Group of Georgia (BMTGA) and Northside Hospital.

For questions, call (404)-255-1930

If you should have questions about the protocol/treatment regimen, please call (404)-851-8238

BMT Protocols - Updated August 15, 2017
  • NSH 1074 – A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantion Followed by Maintencance Therapy with the Novel Oral Proteasome Inhibitor, MLN9708, in patient with High-risk Hematologic Malignancies.
  • NSH 1107 – A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma
  • NSH 1108 – BMT-CTN- 1301-A Randominzed, Mulit-Center Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prewvention of Graft Versus Host-Disease
  • NSH 1125 – A Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma BMT CTN 1302
  • NSH 1132 – A Phase II Trial of Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells For Patients with Hematologic Malignancies
  • NSH 1148 – A Randomized Phase II Study of Autologous Stem Cell Transplantation with Tadalafil and Lenalidomide Maintenance with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
  • NSH 1150 – Phase II trial of Lymphodepletion and Anti-PD-1 blockade to reduce relapse in high risk AML patients who are not eligible for allogeneic stem cell transplantation
  • NSH 1156 – BMT CTN 1501 A Randomized, Phase 2, Multi-Center, Open Label, Study Comparing Sirolimus to Prednisone in Patients with Minnesota Standard Risk, Ann Arbor 1 / 2 Confirmed Acute GVHD
  • NSH 1158 – A Study of T Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide as a Front Line Therapy for Patients with Severe Aplastic Anemia Lacking HLA- Matched Related Donor
  • NSH 1173 – A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients with Advanced Hematological Malignancies
  • NSH 1175 – BMT CTN 1502 Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP)